The Natural History of Anal High-grade Squamous Intraepithelial Lesions in Gay and Bisexual Men
- 28 April 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 72 (5), 853-861
- https://doi.org/10.1093/cid/ciaa166
Abstract
Background: Gay and bisexual men (GBM) are disproportionately affected by anal cancer. Prevention is hindered by incomplete understanding of the natural history of its precursor, anal high-grade squamous intraepithelial lesions (HSIL). Methods: The Study of the Prevention of Anal Cancer, conducted between 2010 and 2018, enrolled human immunodeficiency virus (HIV)-positive and HIV-negative GBM aged ≥35 years. Anal cytology and high-resolution anoscopy (HRA) were performed at baseline and 3 annual visits. A composite HSIL diagnosis (cytology ± histology cHSIL) was used. Cytological high-grade squamous intraepithelial lesions (cHSIL) incidence and clearance rates were calculated with 95% confidence intervals (CIs). Predictors were calculated using Cox regression with hazard ratios (HRs) and 95% CIs. Results: Among 617 men, 220 (35.7%) were HIV-positive, median age 49 years. And 124 incident cHSIL cases occurred over 1097.3 person-years (PY) follow-up (11.3, 95% CI 9.5–13.5 per 100 PY). Significant bivariate predictors of higher incidence included age <45 years (HR 1.64, 95% CI 1.11–2.41), HIV positivity (HR 1.43, 95% CI .99–2.06), prior SIL diagnosis (P-trend < .001) and human papillomavirus (HPV)16 (HR 3.39, 2.38–4.84). Over 695.3 PY follow-up, 153 cHSIL cleared (clearance 22.0, 95% CI 18.8–25.8 per 100 PY). Predictors were age < 45 years (HR 1.52, 1.08–2.16), anal intraepithelial neoplasia (AIN)2 rather than AIN3 (HR 1.79, 1.29–2.49), smaller lesions (HR 1.62, 1.11–2.36) and no persistent HPV16 (HR 1.72, 1.23–2.41). There was 1 progression to cancer (incidence 0.224, 95% CI .006–1.25 per 100 PY). Conclusion: These data strongly suggest that not all anal HSIL detected in screening requires treatment. Men with persistent HPV16 were less likely to clear HSIL and are more likely to benefit from effective HSIL treatments. Clinical Trials Registration: Australia New Zealand Clinical Trials Registry (ANZCTR365383).Keywords
Funding Information
- National Health and Medical Research Council (568971)
- Australian Government of Health and Ageing
- Gilead Sciences
This publication has 31 references indexed in Scilit:
- The Study of the Prevention of Anal Cancer (SPANC): design and methods of a three-year prospective cohort studyBMC Public Health, 2013
- High prevalence and incidence of high-grade anal intraepithelial neoplasia among young Thai men who have sex with men with and without HIVAIDS, 2013
- Human Papillomavirus Infection and the Multistage Carcinogenesis of Cervical CancerCancer Epidemiology, Biomarkers & Prevention, 2013
- Interventions for anal canal intraepithelial neoplasiaEmergencias, 2012
- Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North AmericaClinical Infectious Diseases, 2012
- HPV Vaccine against Anal HPV Infection and Anal Intraepithelial NeoplasiaThe New England Journal of Medicine, 2011
- Trends in anal cancer in Australia, 1982–2005Vaccine, 2011
- HAART and Progression to High-Grade Anal Intraepithelial Neoplasia in Men Who Have Sex with Men and Are Infected with HIVClinical Infectious Diseases, 2011
- Human papillomavirus type distribution in anal cancer and anal intraepithelial lesionsInternational Journal of Cancer, 2009
- Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta‐analysisInternational Journal of Cancer, 2009